Contrasting OSR (OSRH) & Its Competitors

OSR (NASDAQ:OSRH) is one of 89 public companies in the “UNCLASSIFIED” industry, but how does it weigh in compared to its competitors? We will compare OSR to related companies based on the strength of its valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Institutional & Insider Ownership

55.3% of OSR shares are owned by institutional investors. Comparatively, 52.0% of shares of all “UNCLASSIFIED” companies are owned by institutional investors. 60.6% of OSR shares are owned by company insiders. Comparatively, 42.9% of shares of all “UNCLASSIFIED” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

OSR has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, OSR’s competitors have a beta of -0.09, indicating that their average share price is 109% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for OSR and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1	0	0	0	1.00
OSR Competitors	231	266	217	3	1.99

As a group, “UNCLASSIFIED” companies have a potential upside of 101.09%. Given OSR’s competitors stronger consensus rating and higher possible upside, analysts plainly believe OSR has less favorable growth aspects than its competitors.

Profitability

This table compares OSR and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OSR	N/A	-6.66%	-4.90%
OSR Competitors	0.86%	0.95%	0.80%

Valuation and Earnings

This table compares OSR and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
OSR	N/A	-$2.41 million	-0.51
OSR Competitors	$203.60 million	-$18.54 million	94.34

OSR’s competitors have higher revenue, but lower earnings than OSR. OSR is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

OSR competitors beat OSR on 9 of the 13 factors compared.

OSR Company Profile

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.